SI2086945T1 - Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli - Google Patents

Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli

Info

Publication number
SI2086945T1
SI2086945T1 SI200731763A SI200731763A SI2086945T1 SI 2086945 T1 SI2086945 T1 SI 2086945T1 SI 200731763 A SI200731763 A SI 200731763A SI 200731763 A SI200731763 A SI 200731763A SI 2086945 T1 SI2086945 T1 SI 2086945T1
Authority
SI
Slovenia
Prior art keywords
statins
preparation
pharmaceutically acceptable
acceptable salts
novel process
Prior art date
Application number
SI200731763A
Other languages
English (en)
Inventor
Reddy Manne Satyanarayana
Rajan Srinivasan Thirumalai
Reddy Maramreddy Sahadeva
Original Assignee
Msn Laboratories Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msn Laboratories Private Limited filed Critical Msn Laboratories Private Limited
Publication of SI2086945T1 publication Critical patent/SI2086945T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200731763A 2006-10-09 2007-10-05 Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli SI2086945T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1864CH2006 2006-10-09
PCT/IN2007/000459 WO2008044243A2 (en) 2006-10-09 2007-10-05 Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP07859598.0A EP2086945B1 (en) 2006-10-09 2007-10-05 Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
SI2086945T1 true SI2086945T1 (sl) 2016-05-31

Family

ID=39283273

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731763A SI2086945T1 (sl) 2006-10-09 2007-10-05 Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli

Country Status (6)

Country Link
US (1) US8404841B2 (sl)
EP (1) EP2086945B1 (sl)
ES (1) ES2567171T3 (sl)
HU (1) HUE028475T2 (sl)
SI (1) SI2086945T1 (sl)
WO (1) WO2008044243A2 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
EP2086945B1 (en) 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2079712A2 (en) 2006-10-31 2009-07-22 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
AU2008212622B2 (en) 2007-02-08 2011-01-27 Aurobindo Pharma Limited An improved process for preparation of rosuvastatin calcium
KR20090018964A (ko) 2007-04-18 2009-02-24 테바 파마슈티컬 인더스트리즈 리미티드 Ｈｍｇ-ｃｏａ 환원 효소 억제제의 중간체의 제조 방법
WO2009009153A1 (en) 2007-07-12 2009-01-15 Teva Pharmaceutical Industries Ltd. Purification of rosuvastatin intermediate by thin film evaporation and chemical method
SI2387566T1 (sl) * 2009-01-14 2014-07-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo rosuvastatina
EA021942B1 (ru) 2009-01-15 2015-10-30 Эгиш Дьёдьсердьяр Зрт. Способ изготовления солей розувастатина
EP2387561A4 (en) * 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
WO2011086584A2 (en) * 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
WO2011104725A2 (en) 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
AU2011243948B2 (en) 2010-04-23 2014-07-17 Sun Pharmaceutical Industries Limited Novel intermediates for the preparation of HMG-CoA reductase inhibitors
EP2588474A4 (en) * 2010-07-01 2014-07-23 Yuhan Corp PROCESS FOR PREPARING HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
MX357470B (es) 2011-01-18 2018-07-11 Dsm Sinochem Pharm Nl Bv Procedimiento para la preparación de estatinas en presencia de base.
WO2014045294A1 (en) * 2012-09-20 2014-03-27 Inogent Laboratories Private Limited A novel process for the preparation of rosuvastatin calcium using novel intermediates
WO2015037018A1 (en) * 2013-09-14 2015-03-19 Ind-Swift Laboratories Limited Process for the preparation of rosuvastatin via novel intermediates
CN103804414B (zh) * 2014-03-07 2016-04-13 凯莱英医药集团（天津）股份有限公司 用于制备瑞舒伐他汀钙的中间体化合物以及由其制备瑞舒伐他汀钙的方法
CN105153039B (zh) * 2015-07-17 2018-01-12 江西富祥药业股份有限公司 一种瑞舒伐他汀钙中间体杂质的制备方法
CN111454216B (zh) * 2019-10-21 2021-06-29 山东理工职业学院 HMG-CoA还原酶抑制剂及其中间体的制备方法
CN112375102B (zh) * 2020-10-23 2022-05-20 郑州大学 一种可见光催化膦酰化咪唑并吡啶类化合物的制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
JPH0641114A (ja) 1992-05-25 1994-02-15 Nissan Chem Ind Ltd 新規メバロノラクトン類とその製法
GB9314159D0 (en) 1993-07-08 1993-08-18 Zeneca Ltd Chemical process
US5393893A (en) 1993-11-08 1995-02-28 Apotex, Inc. Process for producing simvastatin and analogs thereof
FR2741620B1 (fr) * 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
AU747219C (en) * 1997-01-28 2003-11-20 Plus Chemicals B.V. Process for the production of semi synthetic statins via novel intermediates
ATE392894T1 (de) * 1997-08-28 2008-05-15 Novartis Pharma Gmbh Lymphozyten funktion antigen-1 antagonisten
NO991045L (no) * 1998-03-05 1999-09-06 Synthon Bv FremgangsmÕte ved fremstilling av simvastatin og/eller dets derivater
DK1099694T3 (da) 1998-07-23 2005-09-19 Nissan Chemical Ind Ltd Fremgangsmåde til fremstilling af quinolinderivat og mellemprodukt derfor
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2001282981B2 (en) 2000-07-27 2004-08-05 Plus Chemicals, B.V. Highly purified simvastatin compositions
JP4783998B2 (ja) 2001-05-15 2011-09-28 宇部興産株式会社 （３ｒ，５ｓ）−７−置換−３，５−ジヒドロキシヘプト−６−エン酸の製法
EP1294706A1 (en) 2001-05-18 2003-03-26 Aurobindo Pharma Limited A process for lactonization to produce simvastatin
DE02737324T1 (de) 2001-06-06 2004-07-15 Bristol-Myers Squibb Co. Verfahren zur herstellung chiraler diolsulfone und inhibitoren von dihydroxysäure-hmg-coa-reduktase
CN100349877C (zh) 2001-07-13 2007-11-21 阿斯特拉曾尼卡英国有限公司 氨基嘧啶化合物的制备方法
CA2450820C (en) 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6472542B1 (en) 2001-11-29 2002-10-29 Fermic S.A. De C.V. Method for alkylating the alpha carbon of the 2-methylbutyrate secondary chain of lovastatin
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
DE60326819D1 (de) 2002-01-31 2009-05-07 Novartis Ag Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
AR039836A1 (es) 2002-05-21 2005-03-02 Ranbaxy Lab Ltd Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
TWI343914B (en) 2003-10-03 2011-06-21 Nissan Chemical Ind Ltd Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative
WO2005040134A1 (en) 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
EP1709008A1 (en) 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
US7932387B2 (en) 2005-01-31 2011-04-26 Basf Se Crystalline forms of rosuvastatin calcium salt
US20070037979A1 (en) 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
CN101208307B (zh) 2005-06-24 2012-10-17 力奇制药公司 制备不含杂质的无定型罗苏伐他汀钙的方法
CZ299215B6 (cs) 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
EP1883634A2 (en) 2005-09-13 2008-02-06 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for preparing simvastatin and intermediates thereof
KR101019450B1 (ko) 2005-10-03 2011-03-07 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 부분입체 이성질체 정제
WO2007052309A2 (en) 2005-11-03 2007-05-10 Morepen Laboratories Limited Improved process for manufacturing statins
US20100274014A1 (en) 2006-01-30 2010-10-28 Cadila Healthcare Limited Process for manufacturing rosuvastatin potassium and crystalline and amorphous forms thereof
CN1821242B (zh) 2006-02-16 2012-03-07 亚邦化工集团有限公司 制备二羟基酸HMG-CoA还原酶抑制剂的新方法
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
WO2007132482A2 (en) * 2006-05-17 2007-11-22 Manne Satyanarayana Reddy Novel process for the preparation of pitavastatin and its pharmaceutically acceptable salts
EP2086945B1 (en) 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
CN101386592B (zh) 2008-10-30 2010-08-18 上海交通大学 利用不对称氢化制备匹伐他汀钙原料药的方法

Also Published As

Publication number Publication date
WO2008044243A9 (en) 2008-11-13
EP2086945B1 (en) 2016-01-06
HUE028475T2 (en) 2016-12-28
US8404841B2 (en) 2013-03-26
WO2008044243A3 (en) 2010-02-11
EP2086945A2 (en) 2009-08-12
EP2086945A4 (en) 2010-12-29
ES2567171T3 (es) 2016-04-20
US20100056783A1 (en) 2010-03-04
WO2008044243A2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
EP2086945A4 (en) NOVEL PROCESS FOR THE PRODUCTION OF STATINES AND THEIR PHARMACEUTICAL ACCEPTIC SALTS
EP2024341A4 (en) NEW PROCEDURES FOR STATINE AND THEIR PHARMACEUTICALLY UNINTENTIONAL SALTS
IL206500A0 (en) Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
EP1968943A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF MONTELUCASTAST AND THE PHARMACEUTICALLY SAFE SALTS
ZA200906899B (en) Process for preparation of erlotinib and its pharmaceutically acceptable salts
IL198847A (en) Process for making 2-imino-thiazolidine-4-on and several such histories
ZA200903533B (en) Process for the preparation of rosuvastatin
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
IL194522A0 (en) Process for the preparation of prasugrel
ZA200900336B (en) Process for the preparation of diesters
HK1164292A1 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
ZA200806799B (en) Novel pyrone-indole derivatives and process for their preparation
EP2035410A4 (en) PROCESS FOR PREPARING ESOMEPRAZOLE AND ITS SALTS
IL188919A (en) Process for the preparation of mandipropamide and its derivatives as well as its intermediates
EP2038282A4 (en) SALTS OF PYRROLOPYRIMIDINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
IL200873A0 (en) Novel benzamide derivatives and process for the preparation thereof
EP1883619A4 (en) PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
EP2069307A4 (en) PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS
PL2102174T3 (pl) Sposób wytwarzania pochodnych podstawionych cyjanofenoksy-pirymidynyloksyfenyloakrylanów
ZA200902575B (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
EP2024369A4 (en) NEW PROCESS FOR THE PREPARATION OF SILDENAFIL CITRATE
PL1753720T3 (pl) Proces wytwarzania peryndoprylu i jego soli
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
HUP0700756A2 (en) Process for the preparation of pharmaceutical intermediers
EP2121729A4 (en) PHARMACEUTICAL, SUBSTANTIVE SALTS OF THYMODEPRESSINE AND METHOD FOR THE PRODUCTION THEREOF